Needham downgraded Esperion (ESPR) to Hold from Buy after the company announced it will be acquired by Archimed for $3.16 per share and a $100M contingent value right.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR: